A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications.
UNLABELLED: Our goal was to design and manufacture a kit under good manufacturing practices (GMP) for the preparation of (111)In-DTPA-hEGF Injection, a novel targeted radiotherapeutic agent for advanced epidermal growth factor receptor (EGFR)-positive breast cancer. METHODS: Human EGF (hEGF) was de...
Main Authors: | Reilly, R, Scollard, D, Wang, J, Mondal, H, Chen, P, Henderson, L, Bowen, B, Vallis, K |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2004
|
Similar Items
-
Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer.
by: Reilly, R, et al.
Published: (2006) -
Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor.
by: Bailey, K, et al.
Published: (2007) -
(111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.
by: Costantini, D, et al.
Published: (2007) -
A phase I trial of In-111-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer
by: Vallis, K, et al.
Published: (2008) -
111In-BnDTPA-F3: An Auger electron-emitting radiotherapeutic agent that targets nucleolin
by: Cornelissen, B, et al.
Published: (2012)